Subscribe
shutterstock_1425438833_ii-studio
II.studio / Shutterstock.com
28 April 2020AmericasRory O'Neill

Argentum can't bring Gilenya patent challenge

Argentum Pharmaceuticals can’t have a  Novartis patent for a multiple sclerosis drug invalidated because it doesn’t have standing to bring the challenge, the US Court of Appeals for the Federal Circuit has ruled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

More on this story

Americas
Pfizer fails to establish standing for patent challenge
28 April 2020   Pfizer has been rebuked by judges for filing thin evidence in support of what the pharma company called its ‘self-evident’ standing to bring a patent challenge.
Americas
Novartis tries to block generic versions of Gilenya, enforces new patent
30 January 2020   Swiss pharmaceutical giant Novartis is trying to stop an array of drugmakers manufacturing and selling generic versions of its newly-patented multiple sclerosis treatment, Gilenya.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility